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Hello and Welcome
It is with great delight that I welcome you to this, our 13th Annual Pancreatic
Cancer and Related Diseases Patient Symposium. This is our most special
event of the year. It is with much anticipation that we plan this event. We
welcome back many of our patients, friends, and families. We also welcome
those who are new to Jefferson, and to this symposium.
I hope that you enjoy the contents of this extensive publication, which has
been supervised by our superb Sidney Kimmel Medical College of Thomas
Jefferson University medical students, some of whom may be pancreas
surgeons some day!
In this publication you will find some fascinating stories, interviews, research
updates, and contributions. We are proud to be leaders in the field of
pancreatic and related cancer research, not only clinical research but bench
research, translational research, and epidemiological research. We hope that
you find this day exciting, invigorating, educational, and tasty (we do provide
free breakfast and lunch).
Thank you for celebrating Pancreatic Cancer Awareness Month with us, and
for joining us here at Jefferson as we continue to make an impact in our
fields of research and clinical care delivery. There are many exciting things
going on here at Jefferson Health. It is terrific to see you join us in the fight.
Yours sincerely,

Charles J. Yeo, MD, FACS
Samuel D. Gross Professor and Chairman
Department of Surgery
Senior Vice President and Chair, Enterprise Surgery
Jefferson Health
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PERSPECTIVE
An Interview with Dr. Theresa Yeo, Co-Director of the
Jefferson Pancreas Tumor Registry (JPTR)
BY: NICHOLAS SIENA, CLASS OF 2020
Dr. Theresa Yeo received her BSN from Cornell University in 1976, an MSN from the University of Virginia, and MPH and PhD
degrees in public health from the Johns Hopkins University, Bloomberg School of Public Health.
She spent 30 years of her career in Baltimore, MD, as a Johns Hopkins nurse, Johns Hopkins School of Nursing faculty member,
and researcher before coming to Jefferson with her husband, Dr. Charles J. Yeo, Samuel D. Gross Professor of Surgery.
Since her 2005 arrival in Philadelphia, she has served as an Associate Professor in the Jefferson College of Nursing, Program
Director for Oncology Nursing, Co-Director of the Jefferson Pancreas Tumor Registry, and a nurse practitioner in the Jefferson
Pancreas, Biliary and Related Cancer Center. Dr. Theresa Yeo continues to teach nursing and medical students, mentor
doctoral level students, conduct investigator-initiated research focused on symptom management and quality of life issues
in cancer patients, and publish and disseminate research findings at national and international symposia. She has received
federal, societal, intramural, and private research funding.
Dr. Yeo has published 53 peer-reviewed articles and abstracts and 16 book chapters, and co-edited one cookbook. She is an
Associate Editor of the Journal of Pancreatic Cancer and serves on numerous peer-review editorial boards, including Annals
of Surgery, JOGS, CJON, the Journal for Nurse Practitioners, Oncology Nursing Form, and the Journal of Allied Health. She
was an expert reviewer for the 2018 Kaiser Permanente Research Affiliates Evidence-based Practice Center Project: “Screening
for Pancreatic Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force” (Prepared for the Agency for
Healthcare Research and Quality).
In 2017, she received the Distinguished Alumni Award from Cornell University in recognition of her contributions to the field
of professional nursing.

CONCERNING RESEARCH IN GENERAL
Q: Was it always your intent to become a
researcher or did something along the way inspire
you to change course?
A: It was really just the next step. I was on the faculty
at the Johns Hopkins School of Nursing and the
Dean at that time was Martha Hill who encouraged
the faculty to pursue advanced degrees. I chose a
PhD in public health, as I was particularly interested
in cancer, and the epidemiology of cancer. I was able
to complete my education at the Johns Hopkins
Bloomberg School of Public Health while a faculty
member and the mother of two small children.
Q: You’ve written a paper about mentorship and
mentors. Can you describe your most influential
mentors?
A: One of my most important mentors has been my
husband, Dr. Charles Yeo, who has encouraged me
all along the way and even tutored me in biostatistics.
I could not have completed a dissertation without
his support and that of our family. Charlie’s work
with pancreas cancer patients was very interesting

to me, and led me to get involved in the clinical
care of pancreatic cancer patients and research in
the area.
Q: What qualities did your mentors have that
helped you grow in your career?
A: Being supportive. Letting you know that it wasn’t
necessarily about how smart you are, but how hard
you were willing to work and persevere in what
you want. I also had a great mentor in the Hopkins
School of Nursing, Dr. Candis Morrison, who was
a PhD-prepared oncology nurse practitioner. We
worked together on the hematologic malignancy
service and she had a “you can do this” attitude that
really helped me believe in myself.
Q: Do you have advice for identifying a good
mentor?
A: It’s really important for young people to have
a mentor that they like and one in whose work
they’re interested. We all have informal mentors
in our lives, but the professional ones should be
formalized and that means having ground rules.
It should be clear what is expected on both sides
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of that equation. A mentor has responsibilities and
duties and the mentee has obligations and duties as
well. Sometimes you have to try out a few mentors
before you find the one that is going to work.
CONCERNING PANCREATIC CANCER
Q: What drew you to pancreatic cancer research
specifically?
A: My husband’s career! In the early 1990s the
Johns Hopkins Department of Surgery applied
for and received the first NIH SPORE grant to
study pancreas cancer with Dr. Charles Yeo as the
Principal Investigator. This stimulated a great deal
of research in many related areas. At that time I
was involved with the Hopkins National Familial
Tumor Registry and I was able to use that database
to develop a dissertation thesis, which evaluated
environmental and occupational risk factors for
pancreas cancer in a cohort of familial and sporadic
pancreas cancer patients.
Q: What are the goals of the Jefferson Pancreatic
Tumor Registry and what need did it fill that was
previously unmet?
A: In 2005, when Dr. Yeo and I came to TJUH, there
was not a pancreas tumor registry. We formed
an Advisory Board and in 2008 the IRB approved
the protocol for the JPTR and we began enrolling
patients. Dr. Harish Lavu had recently arrived on
the faculty from Indiana University and UCLA and
served as the first Director of the Registry. Just this
summer we published a descriptive review of the first
10 years of the Registry in the Journal of Pancreatic
Cancer.1 The purpose of the Registry, a longitudinal,
epidemiological study, is to collect information on
hereditary conditions, family history of cancers,
and occupations and environmental exposures to
known human carcinogens. In conjunction with
our Jefferson tumor-banking study, we are also
able to use DNA tumor samples and family history
to make decisions about personalized and precision
therapy. Lastly, we sought to start a high-risk, nonaffected family member surveillance screening
program. Through our annual follow-up surveys, a
community of survivors and their relatives has been
created. It is precious data and we recognize what a
privilege it is to collect these data that describe the
lived experience of people with pancreas cancer
and other related conditions.
Q: Have there been any surprising findings so
far?
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A: There has been much interesting scientific
research from the lab of Dr. Jonathan Brody,
Director of Research in the Department of Surgery.
For example, we have found polymorphisms in a
tumor suppressor gene called WEE1 - SNP indels
in an RNA binding site. Individuals who carry one
specific allele enrichment pattern are more likely
to have first-degree relatives with Lynch-type
cancers.
Q: Is there anything being worked on now in the
field that may dramatically change the detection
or treatment of the disease in the near future?
A: The major treatment advances are going to
be made on the molecular side. Finding out the
molecular mutations and alterations in these
various tumors and developing chemotherapies
that can target those actionable mutations. Early
detection is critical. We encourage all persons with
a family history of pancreas cancer to be under
surveillance by an experienced GI physician who is
familiar with pancreas cancer.
CONCERNING YOUR RESEARCH INTERESTS
Q: Could you describe some of your efforts
regarding quality of life in patients with cancer?
A: This has been an interest of mine for a number
of years. When you work with a cancer population
with high rates of morbidity and mortality you think
about their quality of life and what interventions may
improve it. In 2009, we conducted a randomizedcontrolled trial in post-operative individuals with
pancreas cancer using a home walking program
as the intervention. We randomized post-Whipple
patients to either the home walking program or
to “usual care”, meaning that they could perform
any activity that they wanted. We assessed fatigue
(the number one presenting symptom of pancreas
cancer and also the most persistent symptom
after treatment). Published literature suggested
that walking and exercising helped decrease the
symptom burden in cancer patients and we wanted
to test that theory. We designed and carried out the
study from 2009 to 2011. One hundred and one
patients participated. We found that the group that
walked and/or exercised had less fatigue, weight
loss, anxiety, and depression.2 Based on those
findings, we now routinely give our post-surgery
patients a walking prescription to follow at home.
Q: What has motivated you to devote time to
researching topics like exercise and relaxation in
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Dr. Theresa Yeo hosting the Jefferson Pancreas Tumor Registry information table
at the 2016 Pancreatic Cancer and Related Diseases Patient Symposium

the cancer patient population?

your career in research?

A: There is such a need for this type of research.
Cancer patients deal with difficult situations and
multiple issues. You think to yourself: “What can I
do as a healthcare professional to find ways to help
people?” Exercise has been important in my life for
dealing with stress and improving my own quality
of life. We have a very motivated team of surgeons,
oncologists, nurses, and nurse practitioners
who are interested in helping change lives and
conducting research.

A: Absolutely. I am first and foremost a nurse. I
went to the Cornell University School of Nursing. It
was an incredible, exceptional school. The nursing
education that I received has held me in great stead
for all of my career. In everything I do now, I’m still
a nurse at heart.

Q: What research project do you look back and
feel most proud of?

A: My current position is the perfect blend of being
a clinical nurse practitioner and a researcher. I see
patients in office hours, at the Jefferson Pancreas,
Biliary and Related Cancer Center as part of our
team every week. It is my favorite part of the
position!

A: I was very proud of designing and completing
my dissertation study. The walking study was also a
well-done study. It was an amazing experience to
connect with the patients, to talk with them every
month and to read in their log sheets how they
were doing and what problems they were having.
I think it really helped people.
CONCERNING NURSING
Q: Has your background in nursing helped you in

Q: Is there anything you miss about clinical
nursing that you don’t get from your current
position?

Q: The United States is projected to face an
increasing shortage of physicians in the coming
years. You’ve written that you think this is an area
in which nurse practitioners (NPs) can play a larger
role. Do you think that the medical profession will
welcome a growing parity amongst physicians
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Q: Outside of increasing the role of NPs in primary
care, what are the other areas of clinical medicine
that you think would benefit from an increased
presence of NPs?
A: There is a role for nurse practitioners in both
inpatient and outpatient settings. Just about any
setting is improved by having a nurse practitioner
as part of the staff! The key to being a successful
nurse practitioner, I would say, is to know when to
ask for help, know what you don’t know, and never
pretend to know something you don’t.
Q: You’ve written about the role of advanced
practice nurses in culturally competent care in the
field of oncology. Can you discuss that role and
why advanced practice nurses are uniquely suited
to overcoming or bridging cultural boundaries?

Drs. Charles and Theresa Yeo

and NPs, or do you think there will be resistance?
A: The role of the nurse practitioner can be both
complementary to medicine and can be integrated
into medicine. In my own career, I’ve always felt
welcomed and valued as part of the team. I think
that nurse practitioners can definitely play a
larger role in health care, particularly in areas of
need, such as rural areas where there are very few
physicians. Physician Assistants have a growing
role in this area as well. There is some resistance
from the AMA, to nurse practitioners, but there are
plenty of patients and areas in desperate need of
health care providers to go around.

A: The demographics and cultural backgrounds
of our society are changing. We need a workforce
that can relate to people from many different
backgrounds. Cancer is a much feared disease
and a time when patients and their loved ones
are facing some of the most difficult decisions of
their lives. Having a health care provider who is
culturally aware and sensitive is much appreciated
by patients. Jefferson had one of the only programs
in the country that was focused on preparing
culturally competent advance practice nurses.
Q: What strategies do you think could foster a
greater respect between physicians and NPs?
A: Many schools have started interdisciplinary
programs in which nursing, pharmacy, physical
therapy, and medical students work together on
joint projects. I’ve been involved with some of these
projects here at Jefferson as a faculty member.
Students often know very little about each other’s

Team Jefferson poses for a
picture before the annual
Pancreatic Cancer Action
Network PurpleStride 5K
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role on the health care team, how their roles
overlap, and how they could collaborate. I see that
there is a growing awareness and acceptance of
other peoples’ roles and a greater collegiality as a
result of these initiatives.

button. One of the lessons I have learned in my
career is to not overreact; not every perceived or
real slight needs to be addressed. Choose your
battles carefully and try to be rational, calm, and
diplomatic in your approach.

Q: You’ve looked into incivility in the healthcare
work place. What tactics do you think can cut
down on instances of incivility?

CONCERNING COOKING

A: Incivility is a growing problem in our society.
Each person has to take responsibility for their
own behavior. There are a number of very simple
tactics that can be used: count to ten before
speaking, walk away from a difficult email and think
it through before answering, listen more, talk less,
and be respectful of others’ opinions. When you
have a problem, rather than letting it escalate, go
and speak privately with whomever you are having
the problem. Consider: “Is this their problem or is
this my problem?” Ask yourself, “Who can I really
change?” You can only change yourself. And that
goes back to taking responsibility for your behavior
and being more responsible about how you act in
the workplace.
Q: How have you personally dealt with uncivil
behavior both as a nurse and as a research
scientist?
A: First let me say I’ve been both the perpetrator
of incivility and the object of incivility. No one is
perfect. Remember that you are a professional.
Sometimes it requires you to walk away for a
while, to sleep on it, and to not push the “send”

Q: Your name is on a cookbook of Philadelphia’s
favorite recipes. Do you like to cook?
A: I was honored to be president of the Jefferson
Women’s Board for three years. When I was
president, the major project we undertook for
fundraising was to compile a cookbook about
Philadelphia cuisine. The cookbook featured
Jefferson medical history and Philadelphia’s
culinary past. All of the recipes were submitted by
members of the Jefferson community and they
were all tested. My family tasted many of these
recipes! It was a successful project and great fun.
REFERENCES
1. Yeo TP, Lavu H, Nevler A, et al. Precious Data:
Interim Report from the Jefferson Pancreas Tumor
Registry. Journal of Pancreatic Cancer. 2018;4(1):17-24.
doi:10.1089/pancan.2018.0004
2. Yeo TP, Burrell SA, Sauter PK, et al. A progressive
postresection walking program significantly improves
fatigue and health-related quality of life in pancreas
and periampullary cancer patients. J Am Coll Surg.
2012;214(4):463-475; discussion 475-477. doi:10.1016/j.
jamcollsurg.2011.12.017

Bob Halinski and his daughter,
Stephanie Kensy, stand at the 2017
Ride and Renew event
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A PGY-1’s Perspective:
Conducting Pancreatic Cancer Research as a Medical Student
BY: KEVIN XIE, CLASS OF 2021
Dr. Neal McCall graduated from Sidney Kimmel
Medical College (SKMC) in 2018, and is now in his
PGY-1 year at Emory University for his residency
in Radiation Oncology. Dr. McCall first became
interested in pancreatic cancer research after
listening to Dr. Charles Yeo, Samuel D. Gross
Professor and Chair of Surgery at Thomas Jefferson
University, give a talk on pancreatic cancer during
his first year of medical school. He reached out
to express his interest and was introduced to Dr.
Harish Lavu.
Dr. Lavu served as a crucial mentor for the
formative phase of Dr. McCall’s research career. Dr.
McCall’s foundations in clinical research are due
to Dr. Lavu’s strong influence and guidance, and
he is tremendously grateful to Dr. Lavu for this. Dr.
Lavu not only provided the direction and oversight
to build a research skill-set, but he also provided
enough space for Dr. McCall to grow and overcome
obstacles on his own. This balance led to invaluable
personal growth to which Dr. McCall attributes his
early career success.
Dr. McCall’s first project with Dr. Lavu, titled “Leakage
of an Invagination Pancreaticojejunostomy May
Have an Influence on Mortality,” provided an
archetype of how he would conduct and write
his future projects.1 This experience played an
important role in allowing Dr. McCall to participate
in and contribute to subsequent projects. His time
with Dr. Lavu has developed his skills and given him
a strong foundation in clinical research. Dr. McCall
was involved in several research projects as a
medical student, and recently several of his papers
were published.2,3
Dr. McCall’s interests and research led him towards
oncology, and he dedicated much of his time to
learning and exposing himself to essential aspects
of pancreatic cancer and the surgeries involved.
For Dr. McCall, using his anatomy knowledge and
appreciating the complexities of surgery was a
cerebral experience, and it attracted him from the
beginning. As medical school progressed and he
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learned more about the care of pancreatic cancer
patients, Dr. McCall stumbled upon the world of
radiation oncology.
As Dr. McCall delved deeper into radiation oncology,
his interest in the field grew, and he seriously began
considering it as a prospective career path. He
was drawn to the mix of patients, the variation in
treatment plans, the courses of the diseases, and
the option to cure or palliate. In Dr. McCall’s own
words, “You think about how you’re planning it; you
think about the dose, anatomic relationships, data
collection, and collaborating with other people.
I love those aspects of it, and I love that it’s in a
relatively low-stress environment. That’s how I
thrived on it.”
When asked if there was a pivotal decision point
in his career choice, he had to weigh how the
different aspects of training and his intellectual
interests aligned. Foremost, his passion is in
oncology, and he was sure that he wanted to work
with that patient population and be part of planning
their care. Certainly, the training that medicine and
surgery provide are quintessential for all paths in
medicine, and either would have provided a robust
clinical foundation in treating all patients. However,
Dr. McCall recalled the main deciding factor to
pursue radiation oncology to be the connection
between planning for care and anatomy. “I like
thinking anatomically, and there’s something about
thinking about anatomy that’s really missing for me

GSR November 2018

in medical oncology,” said Dr. McCall. “I love the
science and pharmacology of medical oncology,”
he continued, “but the reality is that you are actually
involved in those things both as a radiation and
surgical oncologist too. You’re just not the one
prescribing them. Regarding research trials, you still
have to see the patients and understand the science
behind it. That’s certainly not missing in surgical
and radiation oncology.”
Dr. McCall knew from the start that oncology was
his passion, and a career in Radiation Oncology
was the right decision for him. The invaluable
experience he had working with Dr. Lavu in
pancreatic surgery provides him with an edge when
it comes to understanding the intricacies of patients
that are surgical candidates. Dr. McCall emphasized
that the planning and decision making involved,
coordination with other disciplines for neoadjuvant
care, and post-operative care are all things he
learned under Dr. Lavu’s tutelage, and these lessons
will guide his perspective on pancreatic cancer
treatment in the future. Although Dr. McCall ended
up not choosing Surgical Oncology as a career, he
and Dr. Lavu continue to collaborate on research
endeavors.
Dr. McCall’s impressive research accomplishments
were an essential aspect of his residency applications,
and lent him a competitive edge. His contribution to
the WARP (Whipple Accelerated Recovery Pathway)
trial was an important component of his application
that captured the attention of his interviewers.
Since many students do not have the opportunity
to contribute meaningfully to a randomized clinical
trial like WARP, the residency programs emphasized
this experience in their interviews. Dr. McCall
recounts that this clinical experience made him
stand out amongst his fellow applicants. “Radiation

oncology is an academic field. Everyone who is
working in academics especially is passionate
about research. It is quite a small field, and because
of that, research is the most important thing, and
it’s hands down the thing that came up the most.”
He also attributes much of his research and interview
success to his work with Dr. Lavu, going on to say,
“I don’t think I would have been as successful in
medical school. I think that building a strong clinical
research background makes you a better doctor
no matter what you do because you’re just able to
interpret evidence better than colleagues who don’t
have that experience. And you’re able to actually
apply it to patients who are right in front of you. So
I don’t think I would have been as successful during
my M3 and M4 years, or even now, just because, in
my opinion, that experience is really foundational
for understanding how to practice medicine as
a whole. Whether you’re in surgery, medicine, or
radiation oncology, that’s a vital skill to have, and
my experience with Dr. Lavu is what developed that
skill overall.”
REFERENCES
1. Lavu H, McCall N, Keith SW, et al. Leakage of an
Invagination Pancreaticojejunostomy May Have an
Influence on Mortality. J Pancreat Cancer. 2018;4(1):4551. doi:10.1089/pancan.2018.0008
2. McCall NS, Dicker AP, Lu B. Beyond Concurrent
Chemoradiation: The Emerging Role of PD-1/PD-L1
Inhibitors in Stage III Lung Cancer. Clin Cancer Res
Off J Am Assoc Cancer Res. 2018;24(6):1271-1276.
doi:10.1158/1078-0432.CCR-17-3269
3. McCall NS, Simone BA, Mehta M, et al. Oncometabolism: defining the prognostic significance of
obesity and diabetes in women with brain metastases
from breast cancer. Breast Cancer Res Treat. July 2018.
doi:10.1007/s10549-018-4880-1

Survivors in attendance at the 2017 Pancreatic Cancer and Related Diseases Patient Symposium
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INTERVIEW
Jonathan Brody, PhD
Pancreatic Cancer Specialist
BY: CARRIE DIANNE WALSH, CLASS OF 2020
Dr. Brody is the Director of Surgical Research and Co-director of the Jefferson Pancreas, Biliary and Related Cancer Center.
He is also the current Chair, Cancer Research Program (PRCRP), Department of Defense (Army) in Washington, D.C. The main
focus of Dr. Brody’s laboratory is to understand the molecular aspects of pancreatic cancer cells and find novel therapeutic
strategies for pancreatic cancer patients.
During his over ten years of training at Johns Hopkins University, Dr. Brody began exploring drug-target interactions. Utilizing
diverse molecular biology techniques that include DNA sequencing, gene knockout and silencing assays, and drug sensitivity
assays, Dr. Brody has published extensively on aspects of chemotherapeutics, namely gemcitabine, 5-fluorouracil, and
platinum-based agents. Part of this work includes his special interest in targeting cancer cells with defects in the BRCA2/
Fanconi anemia DNA repair pathway.
His work also includes advancement in the basic DNA detection technique of DNA electrophoresis, by discovering new
and better alternatives to tris-based buffers, such as lithium-based buffers, that can separate DNA in a fraction of the time
compared to conventionally used conductive media. In relation to gene regulation and mRNA stability, Dr. Brody aided in
cloning members of the pp32 gene family over a decade ago. Members of this family, pp32 and APRIL, have been shown
previously to be ligands and functionally interact with the RNA binding protein, HuR. Currently, Dr. Brody’s work focuses on
how HuR biology is involved in pancreatic tumorigenesis as well as cancer cell survival. His laboratory is also interested in
how HuR expression levels and protein subcellular localization affects treatment of pancreatic cancer. Recently, the group
published work showing that HuR subcellular localization can be potentially a valuable predictive marker for the standard of
care with therapies for this disease. His laboratory’s work is now primarily focused on HuR biology as it relates to the clinical
management of cancer, including identifying clinically relevant HuR targets.
Finally, Dr. Brody is continuing his research in studying drug-target relationships as he is the principal investigator on a 1
million dollar grant (supported by the Pancreatic Cancer Action Network) that supports an unprecedented clinical trial testing
a molecular based, personalized approach to treating pancreatic cancer patients.

CONCERNING RESEARCH IN GENERAL
Q: When did you first develop an interest in
research? Can you describe your general track to
becoming a PhD? Did you make this decision in
high school or undergraduate?
A: I actually attended my undergraduate institution
(Skidmore University) on a music scholarship. I was
a percussionist and I found my passion for music
when I was diagnosed with juvenile rheumatoid
arthritis as a child. I had been a soccer player until
the age of 9 when I developed JRA, which left
me confined to a bed for many weeks during the
summer, not knowing whether or not I would be able
to walk freely again. Luckily it was an acute episode
over one summer and I regained full function, but
it was during that time that my mom’s friend, Linda,
bought me drum sticks and drum lessons. For the
rest of my schooling, I played percussion — I played
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vibraphone, marimba, and drum set.
Arriving in NY from a small town in Maryland, I
appreciated pretty quickly how competitive a career
in music was, and after doing an internship at the
NIH one summer, I realized that many of the things
I loved about music, like being creative, translated
into research. I did think about a career as an MD,
but with so many things in medicine that we do
not have a cure for, I got really interested in cancer
research and trying to help people in this capacity.
I did my PhD at Hopkins, which was mostly
centered around cancer and molecular biology.
For my fellowship, I worked for the researcher who
described more mutations in pancreatic cancer
than anyone in the world. It was through him that
I found myself focused in on pancreatic cancer,
and in fact I was part of the same team at Hopkins
that included Dr. Yeo. Dr. Yeo came to Jefferson in
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2005, and started the pancreatic
research program at Thomas
Jefferson University Hospital.
It was about a year later that he
called me up and invited me to
join his team.
Q: How did you decide between
pursuing an MD vs. a PhD degree
(or both)?
A: I played with the idea of doing
an MD/PhD program, but I fell in
love with being in a lab and doing
research. I guess that I felt that
it would be the best use of my
talents, and the best way that I
could help people.
I have so much admiration for
Dr. Brody with members of the laboratory at PurpleStride
clinicians who treat patients, and in
Philadelphia, hosted by the Pancreatic Cancer Action Network.
fact I did a bunch of volunteering
at various clinics during undergrad,
biomedical sciences, and how the concept of group
but I realized that it was very hard for me to treat a thought and herd mentality can be a bad thing for
patient and then go home and live my life without scientific progress.
becoming emotionally invested.
And finally, my parents are my ultimate mentors,
I enjoy being around people and mentoring as they are true academics and teachers and they
students, but I wanted to push forward in our taught me the principles of: 1) never stop searching
understanding of an untreatable disease, with the for the truth, and 2) teaching is the most important
hope that we can eventually find a cure for our thing you can do to help society.
future patients.
Q: I read that you joined Jefferson in 2006. How is
Q: Who was one of your most influential mentors? your experience at Jefferson the same or different
What lessons did you take from this experience, from your time at Johns Hopkins?
and how do you use these lessons when it comes
A: That is a difficult question to answer because I
to mentoring other students?
did all my training at Hopkins, which meant that
A: I would say that my two most influential mentors I was fulfilling a different role there to the one I
were my drum teacher, and Scott Kern who was my currently hold at Jefferson. I think that Hopkins is
postdoc fellow at Hopkins. Dr. Kern was also part a great place to train, but I also think that whatever
of Dr. Yeo’s group. I think that they both taught me training program or institution you attend, what
that in order to best utilize my talents, to be creative really makes the difference is the people you are
and to perform at my best, I needed to be extremely with, and your mentors/professors.
prepared. In science, this means becoming as
knowledgeable about a subject as possible before I think that the core research faculty at Jefferson are
extremely strong, and in some areas, even stronger
you work on it.
than those at Hopkins. Additionally, people here at
They also taught me the importance of thinking Jefferson are extremely collaborative — as I also
outside of the box, and how this method of thinking found them to be at Hopkins. In fact, many people
helps cultivate creativity both in the arts and in say that Hopkins is very competitive, but I always
science. By constantly thinking in the box, you are found everyone to be extremely cooperative at
not going to be able to make a difference. In fact, both universities.
I wrote an article with my mentor from Hopkins
on herd mentality in science, especially in the One of the similarities between the two institutions
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is that both Jefferson and Hopkins are diverse
enough that if we find something new and
interesting in the lab, I can find someone within
each of the institutions who is an expert. The other
similarity is mostly because of Dr. Yeo. Dr. Yeo has
developed both hospitals into high-volume centers
for pancreatic surgery, which means that we have a
large source of specimens to draw from, along with
a database and important registry.
The multidisciplinary approach of both Jefferson
and Hopkins, which brings researchers and clinicians
together to try and make a difference — not just
patient to patient, but globally — is extremely
important.
Q: I read that you have over 120 publications in
the peer-reviewed literature. What advice would
you give to students, residents, and junior faculty
members who are excited about pursuing a similar
career in research? Would you have different
advice for MDs vs. PhDs?
A: You have to pursue what is exciting for you. I
also think that it is important to like the people you
work for. One of my old mentors from Hopkins, Don
Coffey, used to say, “Whatever you think about in
the shower or when driving your car into work, that
is what you are going to end up being good at, and
that is what you should invest your time in.”
For students, residents, and senior faculty, it is
important to pair up with someone who has
experience. If you see that someone has a good
track record of publishing papers, they ask good
questions, and they are a good mentor - someone
like Dr. Harish Lavu - then connect with them and
get their guidance. You need to find good mentors,
but having said that, I do think that it is hard to
find people who actually care about the process/
question and mentoring and are not just out for
people to give them a paper. As a mentor, you have
to roll up your sleeves and get to it because it is a
two-way street. I am a firm believer that whatever
time I put into students and residents will end up
being an investment in the overall success of the lab
and the work. It is also very fulfilling to see students
and residents get excited about a project and follow
through in the pursuit of trying to answer a good
scientific research question.
The only thing I would say that is different for
MDs vs. PhDs, is that you need to personalize
your educational experience depending on what
program you are studying in.
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The accountability of the student is also important.
I tell students all the time, “It is ok to knock on my
door or email me.” I want that accountability in a
student.
Q: What advice would you give to junior MDs that
are looking to become affiliated with PhDs for
basic and translational research, similar to your
relationship with Dr. Yeo? How did you go about
picking the MDs/Institution to become affiliated
with?
A: I think it is like any relationship, it does not have
to be perfect, but there has to good chemistry,
and you have to have mutual appreciation for one
another. For instance, Dr. Yeo, who for me, is the
epitome of the perfect surgeon — dedicated, on top
of his game, and someone who expects the best
from everyone — respects and appreciates what I
do.
Dr. Yeo, Dr. Lavu, and I are a team with a common
goal to make a difference for this disease, and if
we can accomplish that, then the team wins. So, to
answer your question, I believe that you have to find
people with the same mission and values as you,
and those that respect what each member of the
team can bring to the table.
Q: Was there a moment or project that made
you decide to dedicate your work to focusing on
pancreatic cancer?
A: It was really my experiences at Hopkins that
inspired me to dedicate my work to pancreatic
cancer. This may sound very philosophical, but
pancreatic cancer is one of those diseases that the
more we know the less we know. Even though we
know a lot, there is also a lot that we don’t know,
and for me, the challenge of that is very exciting.
From a researcher’s perspective, the expectations
are high, and although I don’t like these numbers
for our patients, I’d rather dedicate my work to
something where people are given a 9% chance
to live five years vs. a disease like prostate cancer
where patients are given a 90% chance to live five
years.
Pancreatic cancer is a disease that is underrecognized and under-funded. There are not a lot
of advocates out there because patients diagnosed
with the disease usually get angry and then
unfortunately pass away very quickly because of the
poor prognosis that comes with pancreatic cancer.
With long-term breast cancer survivors, they have
time to get angry, time to fight the disease and
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survive, and then years to raise money and spread
awareness. However, for pancreatic cancer, you are
talking about typically a short survival period, which
is heart-breaking, and people just have the time to
get their affairs in order. It is just not fair.
Q: I read that you developed a ubiquitous tool in
DNA analysis. Can you tell me a bit about that?
Was this tool inspiration for some of your future
research?

A: I think collaboration is great. My lab has 54
projects in process, and probably over 20 of them
are collaborations with other institutions. We have
a lot of collaboration with Israel, and now we also
have projects with Kansas, Stanford, Columbia, Fox
Chase, Drexel, and Georgetown. One of the great
things about the pancreatic cancer community
is that we are all very collaborative, there is some
competition (we are all applying for the same
grants), but the camaraderie is there.

A: That project actually came from a mistake that
was written in a lab protocol. I spent months working
with that protocol before I realized that it was an
error. It prompted me to ask the question, “Should
we always accept what is written on a protocol?”
The answer of course is no, we can always make
improvements.

One of my current projects is with Oregon Life
Sciences in Portland. We are writing a grant to create
a live bio bank of specimens, so that we can do
molecular and drug studies on live tumor samples.
It is a huge project, and something we are all very
excited about. I am also part of a precision medicine
endeavor, which is a multi-institutional project.

On realizing the error, I decided that it was
something I could improve upon, and we ended up
making a substitute for a new and better tool. The
published paper allowed us to get a patent. Some of
the students in my lab recently revisited my initial
project and feel that they can better the technique
by using a new technology, so we hope that we may
be able to improve on the tool again.It is because of
this experience that I often tell my students, “Don’t
just accept what is on the written page, always
question whether you can do it better.”

I think that my partnership with Dr. Yeo opened a lot
of doors for me, both nationally and internationally,
and since my lab’s opening, our work has been
strong enough that people want to collaborate
with us. For example, I just returned to the States
from giving a talk in Manchester, UK as I have a nice
collaboration there too.

Q: I saw that you presented on CRISPR at Jefferson
a few years ago. How has the development of this
technology influenced you in recent years?
A: My lab has already published one paper using
CRISPR technology, and both Dr. Jordan Winter
and my lab are on the brink of publishing two more.
From a research stand point, the technology is
revolutionary — a phenomenal tool — and Jefferson
is in the process of establishing a connection with
Christiana Hospital to create a CRISPR institute.
Whether or not it will have a place in clinical
practice is yet to be seen. There is a wonderful
Ted Talk by geneticist Jennifer Doudna that you
should check out. (https://www.youtube.com/
watch?v=TdBAHexVYzc) It is definitely a very useful
tool, but it needs some manipulation to apply it to
the clinical setting.
Q: I saw online that you are involved in multiple
projects with different institutions both in the
United States and worldwide. Can you tell me a
bit about your projects? And your collaboration
between other national and international hospitals?

For the most part, people who go into research in
pancreatic cancer want to make a difference. I think
that we as researchers realize that success correlates
to teamwork, communication, and collaboration. If
you are going to make a difference with this disease
you cannot work in silo.
CONCERNING PANCREATIC CANCER
Q: What do you think have been the greatest
recent advances in the field of pancreatic cancer
medicine and surgery? Do you think there is a
field-changing advancement on the horizon for
pancreatic surgery? For cancer as a whole?
A: I think that the way we are starting to manage
the disease shows that we are getting better at
treating it. The surgery aspect of it at Jefferson
is outstanding, and we are also getting better at
controlling people’s pain.
There are some recent data that have evaluated
different ways of treating the disease. For example,
neoadjuvant vs. adjuvant therapy, or both. Although
not completely decided on, recent studies have
indicated that neoadjuvant therapy might be the
way to go in certain instances.
The
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treatment is still in its early stages. I was part of a
paper that showed that a decent percentage of
patients have mutations that could potentially
respond to drugs that are already in circulation as
treatment for a different disease. There are a lot of
targeted therapies in the lab that I am excited to
move to the clinic, but doing a specific clinical trial
is difficult, especially for the rarer mutations.
I think that our general understanding of the disease
has been enhanced in recent years through our
discovery that pancreatic cancer is not just made up
of tumor epithelial cells, but that there is a tumor
micro-environment that involves things like stromal
cells and fibroblasts. So the main question we now
have is: how do we navigate and target that?
I think there is hope, and I think that there are going
to be some major breakthroughs in the next 5 to 10
years. We keep creeping up in our 5-year survival
percentages, from 6% a few years ago to 9% now.
We are better at managing patients clinically, and I
think that will dove tail when we start being able to
use personalized treatments and expand our drug
arsenal.
Q: In your view, are there any current projects in the
field that may dramatically change the detection or
treatment of the disease in the near future?
A: There are a few projects that are really exciting.
There is a drug called pyrvinium pamoate, which
is currently a treatment for pinworms, which can
target a molecule that is very pro-oncogenic. We
think that it could be a good sensitizer for current
drugs or even act as a monotherapy for treatment
for pancreatic cancer. We are in the process of
completing the pharmacokinetic studies for this
project, and we hope to do a clinical trial next year.
Q: I saw on your Twitter feed that you attended
TRIP18, the first Israel Symposium on Pancreatic
Cancer. Do you find the treatment of pancreatic
cancer to be an international field, and if so, are
there particular groups internationally that have
influenced your research projects?
A: My collaborator in Israel, Talia Golan, (Sheba
Medical Center in Tel Aviv) has a very unique
population. She has the highest volume of Ashkenazi
Jews with pancreatic cancer who have the BRCA2
mutation. She has developed cell lines from these
patients, which she sends over to me so that we can
use them in our lab.
We also have a partnership with Hebrew University
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to study a biochemical RNA binding protein, and of
course our affiliation with Manchester, UK.
OFF THE WALL QUESTIONS
Q: What was your first published paper on?
A: I am really aging myself here! But it was on the
cloning of a gene. This was before the internet,
in the early to mid-90s. My project focused on
cloning this gene and studying its properties. One
of the reasons I am now currently studying the HuR
protein is because it is linked to that gene.
Q: If you could go back in time and tackle your
past projects in a different way, what would you
change?
A: This is something that I often ask myself. I would
say that I tend to be very incremental in my work,
and sometimes I wonder whether thinking bigger is
a good thing. However, there is also a financial cost
to thinking too big too soon, because sometimes
it is the journey that allows you to discover the big
picture.
The pyrvinium pamoate project has taken about
a decade to reach the clinical trial phase because
we got there through a series of steps, and I do not
know if we would have gotten there if we had not
followed that path. In a way, you have to earn those
big ideas and breakthroughs. It is always about the
journey.
Q: Do you still play the drums outside of work as a
release to help you prevent burn out?
A: I used to use the drums as an outlet, but now
with running a lab and having a seven-month-old
at home, it makes it very difficult. When I first came
to Jefferson, I played in a band with the medical
students. I still hold my drum set and want to play,
but for now I use that extra energy to go and listen
to live music.
Q: What other things do you enjoy doing in your
spare time?
A: Traveling with my family. My wife and I, and our
baby, have been to Israel, the UK, and Italy this year.
We were able to link to some scientific conferences.
We are very fortunate that the little one travels well.
And then of course, exercise and listening to live
music. I love to play basketball. A group of the guys
and I will get up and play basketball at 6am. It keeps
me young! I also love running and being outdoors.
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RESEARCH SPOTLIGHT
The Journal of Pancreatic Cancer
by: Harold I. Salmons, Class of 2020

In the realm of oncology, cancer of the exocrine pancreas is an especially lethal malignancy. Annually, exocrine pancreatic
cancer is the third leading cause of cancer death in the United States and the eighth leading cause of cancer death worldwide. As
the organ itself is embedded between key vasculature and digestive and biliary organs, pancreatic cancer is a very challenging
disease to treat. At the moment, surgical resection is the cornerstone of the only curative option for exocrine pancreatic
cancer. Unfortunately, the disease classically presents late, and only a minority of patients qualify for surgery at the time of
diagnosis. Research is therefore a key measure in trying to address this disease and hone its cures.
Efforts are underway worldwide to understand the molecular and clinical manifestations of pancreatic cancer, and further refine
its medico-surgical treatment. The Journal of Pancreatic Cancer (JPC) is the only peer-reviewed journal focused exclusively
on pancreatic cancer. Led by Editor in Chief, Samuel D. Gross Professor and Chair of Surgery at Thomas Jefferson University,
Charles J. Yeo, MD, this international journal offers open-access, peer-reviewed articles covering the clinical, translational,
and basic science of malignancies of the pancreas and the peripancreatic region. The JPC is a terrific resource to surgical
oncologists, pancreatologists, gastroenterologists, radiation oncologists, medical oncologists, endocrinologists, pathologists,
palliative care specialists, epidemiologists, immunologists, and cancer researchers investigating problems and treatments
for pancreatic cancer. From molecular genetics to surgery, this journal offers the most broad and thorough investigation of
pancreatic cancer-related research topics.
The Jefferson Pancreas, Biliary and Related Cancer Center serves as a shining example of what can be accomplished in the
field of pancreatic cancer research. The team of surgeons, oncologists, gastroenterologists, and researchers have emerged
as pioneers in the field of pancreatic malignancies, both through their research efforts and their recognition of key surgical
findings that are uncovered during their operations. This article intends to highlight some of these achievements by casting a
light on a few of Jefferson’s more recent impactful publications in the Journal of Pancreatic Cancer.

Surgeon-Led Imaging Review for Patients with
Periampullary Disease: An Important Aspect of
the Preoperative Consultation1
At surgical consultations, an abundance of radiologic
studies often accompany a patient. Despite being
common practice during patient visits involving
the discussion of upcoming procedures, there is a
paucity of literature specifically investigating the
benefit of incorporating the actual viewing of their
own images by the patient. The possible benefits of
utilizing imaging as a means of educating patients
include facilitation of a better understanding of
one’s diagnosis and more active participation of
the patient in their care plan. This article is the first
to examine these perceived benefits to educate
and include patients in their care plan. In this
study, patients with pancreaticobiliary surgical
consultations were surveyed before and after their
appointments, during which a surgeon scrolled
through CT and/or MRI scans with the patient
and family. Using a five point Likert scale, patients
reported their perceived importance of viewing

their imaging studies and understanding their
medical conditions. Of 51 patients surveyed, 78%
reported they had not previously seen their imaging,
and 55% of patients thought it was important for
them to do so. On average, surgeons spent 2.7
minutes reviewing imaging studies with patients
and family. On the post visit survey, 90% and 86%
of patients, respectively, responded positively
to better understanding their disease and their
planned operation having seen the imaging studies.
After these appointments, almost all patients felt
that the imaging review with their surgeons was
valuable and enhanced their understanding. Based
on the findings of this study, the authors argued
that surgeons should incorporate imaging reviews
into their patient encounters.
Leakage of an Invagination Pancreaticojejunostomy May Have an Influence on Mortality2
Whipple procedures are currently the gold standard
for treating pancreatic ductal adenocarcinoma
(PDA). The most common complication of this
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procedure is a postoperative pancreatic fistula,
which is a leakage of amylase-rich fluid from the
site of the pancreaticojejunostomy (PJ). Among
the three anastomoses performed for pancreatic
reconstruction, the PJ is generally considered
the “Achilles’ heel” of the procedure, due to its
significant importance in patient recovery. There
is no consensus regarding the most effective form
of PJ following a Whipple procedure. To mitigate
the risks of fistula, many techniques have been
studied: alternative anastomotic techniques, the
use and management of intraperitoneal drains,
fibrin glue, and pharmacological agents, but none
have proven definitively effective. The two standard
PJ anastomotic approaches are invagination PJ
(IPJ) and duct-to mucosa pancreaticojejunostomy
(DmPJ). In this study, Dr. Harish Lavu’s team aimed
to retrospectively compare morbidity and mortality
between IPJ and DmPJ using the multi-institutional
American College of Surgeons-National Surgical
Quality Improvement Program (ACS-NSQIP)
Pancreatectomy Demonstration Project. Patients
who received a DmPJ or IPJ differed with respect
to preoperative and intraoperative variables, hence
the groups were not strictly identical. The authors
concluded that IPJ leaks may have a greater
influence on mortality than leaks in DmPJs, and that
further study is warranted.
Pancreatic Mass in a Patient with a History of
Resected Renal Cell Carcinoma and Resected
Adenocarcinoma of the Ampulla of Vater: A Case
Report3
Metastasis to the pancreas from a different primary
cancer site of origin is rare. This report presents a
fascinating case in which a patient with past renal
cell carcinoma (RCC) status post-left nephrectomy
and ampullary adenocarcinoma status postWhipple had a metastasis to his remnant pancreas.
This patient underwent resection via completion
pancreatectomy,
which
revealed
pathology
consistent with metastatic RCC. This paper
discusses the importance of timing in regard to
properly identifying a primary versus metastatic
tumor. Metastasis of RCC to the pancreas often
presents many years after a primary resection.
Conversely, recurrent PDA often presents within
5 years of resection. Additionally, if one resects
the RCC tumor, outcomes are often better than if
one resects a recurrent PDA. The authors of this
paper recommend resecting suspected isolated
pancreatic RCC metastases due to these known
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favorable outcomes, however this is still a highly
debated topic.
Perioperative Management of Factor V Leiden and
Pancreatic Adenocarcinoma4
The perioperative management of a patient with
Factor V Leiden has been infrequently reported.
Further, before this article, there were no reports of
the management of this disorder during pancreatic
surgery. This report was of a 74-year-old woman
with known Factor V Leiden disorder (which causes
increased clot formation), who came to her primary
doctor with pruritis, tea-colored urine, pale stools,
and jaundice for a week. She had a CT-confirmed mass
of her pancreas and underwent a pylorus-preserving
Whipple procedure. She did not have immediate
perioperative embolic or thrombotic phenomena.
Despite being a common hypercoagulable disease,
this was one of the first case reports in the literature
describing the management of a patient with Factor
V Leiden disease undergoing pancreatic cancer
surgery. The successful management of patients
with hypercoagulable states undergoing surgery
involves anticoagulation medications, such as low
molecular weight heparin or a heparin to warfarin
bridge, for a minimum of 3 months. However, the
authors discuss the challenges of avoiding bleeding
events in surgery patients on anticoagulants, and
consequently these risks must be considered while
managing these patients.
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The Mary Halinski Pancreatic Cancer Research Fund and its
Impact on Pancreatic Cancer Research at Jefferson
by: Samantha L. Savitch, Class of 2021
I had the pleasure of speaking with Bob Halinski, founder of the Mary Halinski Pancreatic Cancer Research Fund, and Dr.
Harish Lavu to discuss the state of pancreatic cancer research. Bob founded the Halinski Fund in honor of his late wife, Mary,
who passed away from pancreatic cancer in 2013. Along with his daughter, Stephanie, and son, Luke, Bob hosts a fundraiser
every year called “Ride and Renew” to raise money for research endeavors at Jefferson and educate the community about
this important disease. Bob is the recipient of the 2018 Community Impact Award for his work as a fundraiser and advocate.

Q: Bob, you clearly developed a strong relationship
with the physicians at Jefferson who took care
of Mary. Can you describe what brought you to
Jefferson in the first place and how you met Dr.
Lavu?
BH: We went to Jefferson based on the
recommendation of our PCP, largely because
of Dr. Charles J. Yeo’s reputation. We made an
appointment as soon as we could after the initial
diagnosis. Interestingly enough, when Mary went
down [for] a procedure to put a stent in, because
she was having a blockage, we had assumed we
had made the appointment with Dr. Yeo, but then
Dr. Lavu came into Mary’s room while she was
recovering from the procedure. And at that point
there was an instant connection. Dr. Lavu had
a wonderful bedside manner and seemed very
intelligent, and had a very calming demeaner.
Over the course of Mary’s treatment at Jefferson,
the two of them really developed a patient doctor
relationship, they befriended one another.
Q: Dr. Lavu, what do you remember about Mary
from that first encounter?
HL: I remember Mary as just an unforgettable type
of person. Mary was a high energy person, a person
who just has a thousand-watt smile, that kind of a
person. We hit it off right away.
Q: Bob, do you think that relationship played a big
role in how your family was able to deal with the
course of the disease and the hospital visits?
BH: Definitely. Really all of the physicians down
there, including the nursing team, but Dr. Lavu
mainly for the surgical management and then on
the medical side Dr. Edith Mitchell, who again had
a wonderful bedside manner with Mary. Mary was
always a pleasant person, easy to get along with,

and people just gravitated toward her, and she just
befriended Dr. Mitchell too and they became friends.
We had many visits with her, a lot of it was just, not
only the medical part, but on the personal side too.
I think it helps to know you’re in good hands, and
there’s a compassion there that’s real. It’s not a
forced compassion. The way I viewed it, and I know
Mary viewed it, it was real compassion for patients,
real compassion for Mary, and when I go to these
symposiums and am sitting around the table there
and talking to patients or caretakers, they all have
the same message: not only great clinical care, but
the compassion they feel. And I think that is helpful
in dealing with the diagnosis.
Q: How has your relationship with each other
changed over the years?
BH: It’s interesting, Mary had the connection, not
that Dr. Lavu and I didn’t have a connection, but we
weren’t as close, so to speak. I think that once Mary
passed, not only was it tough on me, but I think
on Dr. Lavu, it really moved him, and it was tough
on him because he really wanted Mary to survive
longer than she did. I know that the doctors have to
be professional, but you’re human too, and I think
by establishing the fund, I was able to continue the
relationship with Dr. Lavu, where we’ll touch base
periodically on a friendship basis, and partly also
on a professional basis, as far as getting updates
on where things are going with pancreatic cancer
research. So I sort of stepped in the shoes of Mary
a little bit, not so much because that was a special
relationship they had, but I call Dr. Lavu a friend and
I think likewise he probably feels the same about
me.
HL: We’re very close, because we shared an
experience. Obviously, Bob was there every step
of the way for his wife. We developed a closeness
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through that process that lasts to this day.
Q: While Mary was going through treatment, were
there any experimental options that were offered
to her?
BH: There were some clinical trials that were made
available. Mary was in a couple different ones, but
not anything groundbreaking. One that Mary didn’t
do, and I think there was a little bit of disappointment
on Dr. Lavu’s side and some of the researchers there,
was a vaccine trial that was going on. Mary was a
clinical person, she worked at a pharmaceutical
company, she had a science background, so she
understood all of that. I’m a finance person so it
was always difficult for me. But for that one clinical
trial, we both did our own independent analysis of
it, and came back with the conclusion that we didn’t
think it was worthwhile. There was no regret on the
decision. You make the decision based on what you
have. We never second guessed that. We just trusted
our judgment. Sometimes you have to face what’s
staring in front of you.
Q: Tell me about Mary’s background. I hear she
was a big player in patient advocacy. What drove
her to be so involved in the community?
BH: Part of it is just her personality, it’s just her
character and her makeup. She was just a giving
person. She always looked to help others. She would
help not only to take care of me and my two children,
and her mom, but she was just a giving person across
the board. My son had a lot of health issues when he
contracted undiagnosed Lyme disease, and he had a
lot of pretty significant adverse manifestations from
that, and she took it upon herself to be an advocate
for patients. She was very good politically – reaching
out to federal legislators, state senators, and trying
to get legislation that could direct funding toward
Lyme disease research. She just liked helping people.
Every day of her life she liked to help people.
Q: How did the idea for the Mary Halinski Fund
come to be? What did it entail to put it in place?
BH: Mary really appreciated what Jefferson was
doing for her, and the care that was being provided
throughout her whole treatment, so she made
donations to the existing Jefferson pancreatic
cancer research fund. After she passed away, [I
thought about] her whole legacy of giving and
being an advocate for patients, for people, and
helping people across the board. Laura Goldstein
[of Jefferson’s philanthropy department] had
reached out to Mary thanking her for the donation,
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so I sent a note to Laura, and said, “Hey, if I want
to do something in Mary’s name, what could I do?”
The idea of a research fund in her name just seemed
like the perfect fit, for me and for Mary. It kept her
legacy of giving alive. She loved science, she loved
learning, she loved helping people. And I thought if I
start an endowed fund in her name, what better way
to honor her legacy? If research advances are made
by the Jefferson research team, and it’s published
and they make advances at some point, I would
love Mary’s name to be part of that. And that’s why
I thought that was the way to go. And I felt really
good about it, and it helped me. When somebody
you love dearly passes away, this is a way to have
some positive come out of, and it accomplished
that. It helped me in the healing process to try to
move forward, and the continuation of the fund has
been helpful. And the thing that’s amazing is there’s
a lot of things in this world that don’t go right, but
there’s a lot of goodness in this world too, and when
you establish a fund like this, it’s just nice because
people step up to the plate.
Q: What does the fund look like now? What are the
main goals and what types of events are associated
with it?
BH: Our fund is not the largest fund in the world, but
it’s a start. I think part of the fund is to use it to seed
research. To get the multimillion dollar grants, you
have to have a testing ground to prove to whoever is
providing that grant, whether it’s a private foundation
or the government, people want to see, “Is this going
to work?” That’s really what our money is being used
for. The main fundraiser every year, which we started
a couple years ago, is called “Ride and Renew”. It’s
a one-day event, and it’s a combination of indoor
cycling, spin classes, and yoga classes. I’ve become
an avid cyclist and yoga is great for me to improve
my health and has helped me move forward after
Mary’s passing. My daughter also enjoys cycling and
recently became a certified licensed yoga instructor,
so we just found that this would be the right fit for us
to have some forum to raise money, help physically
and mentally too, and it gave us a venue to get the
word out. We just want to get Mary’s name out there
and keep her name alive, but also let people know
about pancreatic cancer. As you know, it’s so lethal.
All cancers are bad, but this one seems particularly
lethal. I don’t think people know that, and when they
hear the statistics, it touches them. So that’s what
we do, and this will be our third year now. It’s been
received pretty nicely, and we’re happy about it.
This year’s “Ride and Renew” will be held on Sunday,
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November 18th.
Q: What has your involvement in the pancreatic
sphere been outside of the fund?
BH: I just support the other organizations. I support
their events. I try to show up to those, any one that’s
local that I can drive to I’ll usually go and support
people. Everybody just sticks together on that. I’m
not active in any other way than participating and
making contributions to those funds. I like the money
to go to Jefferson, but these other organizations do
wonderful things too.
Q: You’re being given the Community Impact Award
at this year’s Pancreatic Cancer Symposium. Can
you tell me a bit about when you found out about
that award and what it means to you?
BH: I received a letter from Dr. Yeo directly telling me
about this inaugural award and that they’d like me to
be the recipient and outlining why. My first reaction
was, “You guys don’t need to do this.” I appreciate
the award, but I just want to do what I’m doing and
help. But I am grateful for the acknowledgement,
because I do try to make an impact. But it’s about
Mary and it’s her award and her fund, and it just
needs to be about her. The thing I like about it is, if in
the course of getting this award and telling my story,
maybe it can help people who have gone through a
pancreatic cancer diagnosis move forward. Maybe
people will think, “This guy encountered this and
he’s doing pretty well and trying to make a positive
out of a negative.” And that actually makes me feel
good about this.
Q: Dr. Lavu, how has Bob’s work influenced the
community and how does he embody this award?
HL: The thing that’s been really impressive is that
Bob went through this experience with Mary, [and]
he could have left it with that and just let it be. But
he decided he wanted to do something, along with
his daughter, Stephanie, and his son, Luke. And not
only have they supported research and donated
their own money, but they’ve hosted a fundraiser
which serves the purpose of raising money and
getting education out there to the community.
And to me that’s so amazing. That’s so critically
important, because people out there don’t know a
lot about pancreatic cancer. I’ve been able to attend
a number of the events that Bob and Stephanie have
put on, and they’ve been great. And then Bob has
been supportive of other families and other groups
who have put on their events. We’ve met at other

people’s events, he’s been supportive of them. He’s
one of these glue people, I think, a person who
brings other people together, that’s how I think of
Bob. I just think it’s really fitting that he’s getting this
award.
Q: What do you see as the biggest impact that the
fund has had on the pancreatic cancer sphere?
BH: Just in general, when I hear about some of the
small advances that they’re making in findings, I just
feel really good. I know the research takes a while
to run its course to really make a difference, but
what I like is when I hear the little advances they
discovered in six months and how they plan to use
it, that’s what excites me. I get reenergized. I sit
down with the researchers every six months, and
when I leave there, I think, “Okay we’re making a
difference here.” You publish this, other researchers
will look at it, and they will say, “I like that idea let’s
run with this coupled with something else.” That’s
how I view the fund.
HL: It’s been tremendous helping us continue our
pancreatic cancer research here. The things we do
clinically, we work together with our basic scientists
such as Dr. Jonathan Brody. And the Halinski Fund
covers the funding for young researchers to carry
on this work and to train the next generation of
researchers and basic scientists. Ultimately, the next
great leap forward will come from a laboratory. And
we all know that, even as clinicians as we take care
of patients every day. So for us, it’s very important to
have a fund like that.
Q: Dr. Lavu, what does the field of pancreatic
cancer research look like right now?
HL: Pancreatic cancer is being attacked on
so many different fronts, whether it’s early
detection strategies, whether it’s new targeted
therapies, whether its understanding how to use
chemotherapy more effectively. In the surgical field,
in the last ten or fifteen years, we’ve become much
more aggressive in the kind of surgeries that are
being done. We’re doing more minimally invasive
surgery. We understand how important it is to get
the patients through recovery so they can get on to
adjuvant therapy. And that has improved lightyears
in terms of postoperative and preoperative care.
Ultimately, there will be breakthrough medications
that will be developed that will put pancreatic
cancer more on a par with breast cancer or colon
cancer, which are cancers that are treated in
very similar ways to pancreatic cancer: surgical
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resection, chemotherapy, sometimes radiation
therapy. But the main difference is that, for those
cancers, the chemotherapy is incredibly effective,
and for pancreatic cancer we’re not there yet.
Q: What is a reasonable goal for five years from
now?
HL: We know that the incidence of pancreatic
cancer is rising. By 2020 it will be the second
leading cause of cancer death in the US. And that
is being driven by demographic forces: the aging
population, aging smokers, and then the crisis of
obesity and metabolic syndrome. All of these are
driving pancreatic cancer development. When I
first had the inkling that I might even be interested
in this field, 18 years ago, the number quoted in
research papers for five-year survival was very low,
but it has been slowly inching up since. In five years,
my hope is we can double the survival rate that we
see today, because the pace of knowledge, the pace
of scientific research is accelerating. I think that’s
a reasonable and realistic goal. In fact, I want it to
be better. I hope it can be even better. I hope I’m
underselling it.
Q: Are there any recent findings or research on the
horizon that could prevent stories like Mary’s from
happening?
HL: There was literally a breakthrough in our
understanding of adjuvant therapy for pancreatic
cancer just three months ago. A large-scale,
multicenter trial showed that combination
chemotherapy, that people thought was too
aggressive for patients after surgery for pancreatic
cancer, it turned out it did a fantastic job in
preventing recurrences and prolonging people’s
lives. That was a huge, huge breakthrough. And it
changed the standard of care almost overnight.
The patients we see today are being advised to
get a combination chemotherapy that they were
not advised to get in May of this year. That’s how
quickly it’s changed. And that’s why I say the pace
of development is accelerating in our society, for
everything, and I think that it will serve to help
pancreatic cancer care.
Q: I read that the Halinski Fund contributed to the
Jefferson study looking at HuR. How influential
has the Halinski fund been on pancreatic cancer
research at Jefferson?
HL: I think [the fund] has been a pillar of helping
support pancreatic cancer research here at
Jefferson. And the HuR story is one of the
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important molecular themes in pancreatic cancer
development. Dr. Brody’s lab is amongst the world’s
leaders in understanding HuR. I just think it’s very
exciting, and I know that the researchers who are
being funded to be able to do this work through the
generosity of the Halinski fund, these are your next
generation of GI cancer researchers. So I just think
it’s an immeasurable impact.
Q: What do you each see as the role of health care
professionals in these kinds of funds?
BH: Awareness. Physicians, your focus, and rightly
so, is on the clinical aspects of it, and trying to heal
the patient or make their quality of life better. That’s
why you go to medical school, to treat patients. But
I think that for a fund like this, the physician’s role
is just to let patients know that there are funds like
this, that are helpful for your ability to give back,
or make a positive difference. So don’t be averse
to it. People say that’s the development people’s
job to raise money and awareness. But I think the
physicians need to collaborate and work and I think
Jefferson does a good job of that, you know the
balance between the need to get funds for research
and help as best they can.
HL: I think that the bottom line is I’m in the field of
pancreatic cancer care as a doctor, as a surgeon, as
a researcher. And philanthropy is one of the ways
that one advances the field. If you look at funding
for cancer research from the NIH, pancreatic cancer
is tremendously underfunded. The NIH and the NCI
have not caught up with the proper funding levels
to look for the breakthroughs that we have gotten
for breast cancer, for colon cancer, for melanoma.
There are amazing stories out there for some of
these other types of cancers, and most of those
stories started in basic science labs. So philanthropy
is one of the ways that pancreatic cancer research
is being conducted these days. My role is to get that
message across.
Q: Dr. Lavu, as a healthcare provider, how would
you bring up philanthropy to a patient, student, or
other person in the community?
HL: I think that different doctors do it in different
ways and have different comfort levels. Certain
people have a natural ability to bring up things like
that. I do think it’s important to recognize though
that when you’re caring for a patient, for a family,
it’s really critical that you have a close bond and
it’s all related to medical care. The philanthropy
picture is something that comes up later on, down
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the road, when your direct care is mostly finished
at that point. But oftentimes patients or families will
say, “What can we do to help?” And there is a lot
of research that shows that people who have been
through a medical condition or family members,
there’s a feeling of helplessness. Because you’ve
gone through this thing, and maybe you’ve made it
out the other side, but you feel like, “What can I do
to help other people?” And there’s a lot of research
that says that being involved with philanthropy is
tremendously healing for patients that undergo
these traumatic medical experiences of having
illnesses. So for the people who are interested in
that way, I enjoy chatting with them about it.
Q: What would you say to people who are interested
in their own funds or donating to funds? What is
the process like?
BH: If you’re thinking or inclined to be doing
something, really think about it seriously, because
you’re going to feel good about it. I always tell folks
to act upon that, whether its setting up a fund in a
loved one’s name, that’s great, but Jefferson has a
wonderful existing fund too. And it really does make
a difference. Every dollar counts. Jefferson is really
good stewards of that money, and they are using
it essentially 100% for research. It’s not going to
overhead or anything else. And the process is very
simple, but can be pretty customized to what your
needs and desires are. The development team is just
really nice to work with.

HL: We have a liaison between our surgery
department and the philanthropy office at
Jefferson. They work very closely with us because
they’re involved in helping run a lot of pancreatic
cancer awareness events and things of that nature.
So if a patient or family member is interested, I’ll just
serve as the person who puts two people together.
Q: Is there anything else you want people to know
about Mary or the fund?
BH: Mary was just a special person. She just gave so
much of her time for others. She volunteered, she
was a very strong person of faith, and she relied on
that to help her deal with everything. She donated
a lot of time to her church, and she visited nursing
homes and the elderly and prayed with them as part
of the Catholic faith. She donated her time to going
down to the soup kitchen to feed the homeless.
She just helped people all the time. That’s who she
was. She was a selfless person, but very positive too.
She’d make friends instantly. She went to jury duty
and she got there and had all these friends. And I
was like, “How did you make friends with jurors so
quickly?” But that’s the person she was. She just
connected with people. She was selfless and giving
and had a strong faith in God and it was wonderful
to see that. And it’s helped me and motivated me
in lots of ways. And that’s why this fund is a way to
continue to honor her. She loved to give to people
and give herself, and this is the perfect thing for her.

Bob and Mary Halinski in August of 2011
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THE GIBBON SURGICAL SOCIETY
The John H. Gibbon, Jr. Surgical Society (GSS) at Sidney
Kimmel Medical College (SKMC) at Thomas Jefferson
University is a unique student interest group that has
been working hard to increase interest in the field of
surgery among medical students for the last 37 years.
The society has over 400 total active members on a year
to year basis, spread across the four-year curriculum.
The GSS increases exposure and interest to the surgical
field through a unique blend of episodic and longitudinal
programming that helps bring together students,
residents, and faculty in an educational setting.
The crux of the GSS approach to bolstering medical
student interest is early exposure. Over the years, the GSS
has run many programs specifically targeted at students
in the pre-clinical curriculum to increase surgical
exposure. Potentially the most influential program is
Surgery at Night, which provides an opportunity for
students to spend an overnight shift with a surgical
resident and intern early in their medical school career;
there are typically over 200 such overnight stays by
students in an academic year. Students frequently have
the opportunity to scrub in on emergent cases and are
often instructed in suturing small incisions at the end of
cases. Another excellent opportunity for students is the
Organ Procurement Program, in which all students who
receive the necessary training are signed up for a lottery
that allows them to travel and scrub in with the organ
procurement team. The most innovative program that
has been started by the GSS is the SCALPELS program,
in which faculty members and upperclassmen plan a
longitudinal surgical curriculum that runs concurrently
with the pre-clinical curriculum, and offers surgeryspecific lecture topics and skill sessions relevant to the
underclassmen’s studies.
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There are also events that are available to all students.
The GSS runs a quarterly journal club, which is led by a
surgeon at Jefferson in the field that is currently being
studied by the second-year medical students; typically,
one “classic” article from the literature is discussed
and contrasted with a contemporary article. The basic
anatomy and physiology are presented by a first- and
second-year medical student, and the findings of the
papers are reviewed by a third-year medical student.
Many surgeons take this time to not only educate the
students in critical review of the findings of papers,
but also the underlying statistics that were used. The
Philadelphia Surgical Symposium is the GSS’s signature
event and is run in the spring of each year. Students
from all medical schools in the Philadelphia region (six
schools in total) are invited, and it is intended to be an
informative opportunity for medical students interested
in surgery. There is an associated regional medical
student research poster session and competition
during the event, complemented by presentations from
a faculty member from each school, ranging in topics
from clinical experiences, to advocating for a particular
field of surgery, to hot topics in research. The event
concludes with a two-hour networking session, either
on site or at a nearby venue.
The GSS was presented at the AAMC’s Learn, Serve, Lead
2017 conference as a model for an effective medical
student interest group. This journal, the GSR, is written,
compiled, and curated by SKMC students through the
invaluable help and planning of the GSS members, and
stands not only as a testament to the involvement and
hard work of the GSS, but also of the student body as a
whole.
-Tyler M. Bauer, Class of 2020
Senior Editor
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CHARLES J. YEO, MD, FACS
Dr. Charles J. Yeo was born in East Orange, New Jersey,
and attended Spring Valley Senior High School in
Spring Valley, New York. He received his undergraduate
degree from Princeton University in 1975, summa cum
laude, with an A.B. in Biochemistry. Dr. Yeo graduated
in 1979 from the Johns Hopkins University School of
Medicine, being awarded the Upjohn Achievement
Award, and was elected to Alpha Omega Alpha and Phi
Beta Kappa. He went on to complete his residency in
General Surgery and a fellowship in advanced GI and
vascular surgery at the Johns Hopkins Hospital.
Dr. Yeo joined the faculty of the Johns Hopkins
University as an Instructor and Assistant Chief of
Service in the Department of Surgery in 1985, and
rose to the rank of Professor of Surgery in 1996. Dr.
Yeo directed the Pancreatic Cancer Interdisciplinary
Working Group at Johns Hopkins and served as
the Surgical Clerkship Coordinator and Surgical
Curriculum Consultant. In 2001, Dr. Yeo received the
Alumni Association Excellence in Teaching Award from
the Johns Hopkins University School of Medicine. In
2002, Dr. Yeo was named to an endowed chair at Johns
Hopkins, becoming the inaugural John L. Cameron,
MD Professor for Alimentary Tract Diseases.
On October 1, 2005 Dr. Yeo was named the 8th Samuel
D. Gross Professor of Surgery, and he assumed the
chairmanship of the Department of Surgery at Sidney
Kimmel Medical College at Thomas Jefferson University
in Philadelphia, Pennsylvania. He currently serves on
the Board of Trustees of Thomas Jefferson University
Hospital.
Dr. Yeo’s academic accomplishments include being
Editor-in-chief of Shackelford’s Surgery of the
Alimentary Tract, 8th Edition, being an Associate Editor
of Advances in Surgery and past Co-Editor-in-Chief
of the Journal of Gastrointestinal Surgery, and serving
on the editorial boards of Langenbeck’s Archives of
Surgery, Surgery, and Annals of Surgery. He is the author
of over 550 peer-reviewed scientific papers, numerous
abstracts, over 105 book chapters, and 24 books and
monographs.
Dr. Yeo’s primary interests and research have been
in the field of alimentary tract surgery, focusing on
hepatopancreaticobiliary surgery - the evaluation of
patients with pancreatic, biliary, and related cancer, and
the management of patients with unusual pancreatic
neoplasms, as well as acute and chronic pancreatitis.
He travels nationally and internationally teaching and
lecturing on the treatment of benign and malignant
pancreatic diseases and has personally performed
over 1550 Whipple operations.
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To learn more about supporting pancreatic cancer research or clinical care
at Thomas Jefferson University Hospital, contact Kelly Austin, Director of
Development, at 215-955-6383 or Kelly.Austin@jefferson.edu.

